Artis Ventures, a San Francisco, CA-based venture capital firms that partners with entrepreneurs driven to impact the world by reshaping and reinventing industries, announced the close of its fourth fund, TechBio II, at $200m.
This new fund is solely focused on the TechBio sphere – an industry defined by companies using data, software, AI, machine learning, and deep learning to transform human health and well-being.
The firm’s TechBio investment process is guided by the following principles:
- Think Globally, with the next set of high-impact companies will focus by definition on improving care universally
- Leave No One Behind, targeting disease areas that many times lack solutions today
- Transform Systems, focusing on innovations across the healthcare spectrum from the hospital to the home – leveraging data and personalization to radically improve care delivery wherever it occurs
- Embrace Diversity, with over 60% of its portfolio company founders representing marginalized groups
- Persist Despite Obstacles, partnering with bold founders ready to overcome barriers through tenacity and grit
- Stay Focused, navigating regulated fields like healthcare and biology demands focus, specialized expertise and strategic insight.
Led by Stuart Peterson & Vasudev Bailey, Managing Partners, Artis Ventures funds companies at the intersection of computer science and life science, applying engineering principles and data-enabled discovery to healthcare. The team supports its portfolio companies through their entire life cycle, from initial venture investment to public offering and beyond.
Notable companies the firm has backed include Stemcentrx (acquired by Abbvie), IDbyDNA (acquired by Illumina), Lemonaid Health (acquired by 23andMe), Outpace Bio, SEED, RadAI, Tessera Therapeutics, Freenome, Eko, Delix Therapeutics, Modern Meadow, Excision BioTherapeutics, and more.